Bozeman, Montana Feb 5, 2025 (Issuewire.com) - Alercell, a leader in molecular diagnostics and artificial intelligence in oncology, is proud to announce the launch of its newly designed website www.alercell.com. The site offers a comprehensive look at Alercell’s groundbreaking work in AI-powered leukemia diagnostics and precision medicine solutions.
Alercell is actively advancing the development of its proprietary Deep Leukemic Cloud Platform—an AI-driven system designed to revolutionize early cancer detection. Our ongoing research and innovation aim to achieve over 97% accuracy in identifying leukemia markers, with the potential to detect them up to 41 weeks before symptoms appear.
The new website provides insights into Alercell’s cutting-edge diagnostic tools, including:
✅ LENA Q51 – An advanced test delivering leukemia gene signature results within hours
✅ LENA S1 – A next-generation platform for NSCLC gene methylation detection
✅ LenaDX – A clinically validated leukemia testing solution
“Incorporating AI into cancer diagnostics is a game-changer,” said Frederic Scheer, CEO of Alercell. “With our Deep Leukemic Cloud Platform, we’re not only improving early detection but also providing actionable insights that can guide personalized treatment strategies. Our new website reflects our mission to make these life-saving technologies accessible to the medical community.”
Accelerating the Fight Against Cancer
Alercell is actively advancing its research and seeking $10M in funding to bring its innovative solutions to market, expand clinical trials, and accelerate regulatory approvals. The company is collaborating with leading institutions, including experts from MIT, Columbia University, and Memorial Sloan Kettering Cancer Center.
Explore the Future of AI in Diagnostics
Healthcare professionals, researchers, and investors are invited to explore Alercell’s innovations and the impact of AI-driven diagnostics at www.alercell.com.
About Alercell
Alercell is a pioneering force in preventative oncology, dedicated to transforming cancer detection and intervention through cutting-edge technology. With a mission to “stop it before it starts,” Alercell integrates AI-driven diagnostics with genetics-based testing to revolutionize early cancer and leukemia detection. In 2024, the company took a major leap forward by incorporating artificial intelligence into molecular diagnostics, reinforcing its commitment to improving patient outcomes through early intervention.
By leveraging advanced AI, precision medicine, and molecular insights, Alercell is redefining the future of oncology diagnostics, ensuring that patients receive the best possible chances for successful treatment—right from the start.
For more information, visit www.alercell.com and www.Lenadx.com.
Media Contact
Alercell Inc. fscheer@alercell.com 4069208787 5 West Mendenhall Ste 202 http://www.alercell.com
